The Role of Bosutinib in Chronic Myeloid Leukemia: An Indian Perspective
Management of chronic myeloid leukemia (CML) has been transformed by the use of tyrosine kinase inhibitors (TKIs). Presently in India, five TKIs are approved for the management of CML with distinct safety profiles. The selection of TKIs for chronic phase (CP)-CML patients is based on treatment goals...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2024-08-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0042-1756477 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849336999353253888 |
|---|---|
| author | Mohan Bajranglal Agarwal Manthanathu Joseph John Punit Jain Ashok Kumar Vaid Ajay Bapna Maheboob Basade Palanki Satya Dattatreya Anupam Chakrapani Vijay Ramanan R. Varadarajan Murali Subramanian Chirag Aniruddha Shah Narayanakutty Warrier Subhaprakash Sanyal Tyavanagi Shankarmurthy Ashwin Nagendra Ramanjinappa |
| author_facet | Mohan Bajranglal Agarwal Manthanathu Joseph John Punit Jain Ashok Kumar Vaid Ajay Bapna Maheboob Basade Palanki Satya Dattatreya Anupam Chakrapani Vijay Ramanan R. Varadarajan Murali Subramanian Chirag Aniruddha Shah Narayanakutty Warrier Subhaprakash Sanyal Tyavanagi Shankarmurthy Ashwin Nagendra Ramanjinappa |
| author_sort | Mohan Bajranglal Agarwal |
| collection | DOAJ |
| description | Management of chronic myeloid leukemia (CML) has been transformed by the use of tyrosine kinase inhibitors (TKIs). Presently in India, five TKIs are approved for the management of CML with distinct safety profiles. The selection of TKIs for chronic phase (CP)-CML patients is based on treatment goals, underlying comorbidities, and specific TKI toxicity profiles. Bosutinib is one of five TKIs indicated for the first-line treatment of CP-CML and patients with intolerance or resistance to prior TKI therapy. It possesses a distinct safety profile among other TKIs, with less cardiovascular adverse events (AEs), albeit the liver-related and gastrointestinal AEs have higher occurrence. The safety and efficacy of bosutinib have been examined in clinical trials; however, there is a paucity of data from Asia. A virtual expert panel meeting was convened to gather expert opinion from India on the selection of bosutinib as a treatment choice for patients with CP-CML. This is a white paper document drafted with the help of an expert panel of 14 oncologists and hematooncologists from India on bosutinib use in CP-CML. The experts concurred that bosutinib has proven efficacy for CP-CML in global randomized clinical trials and is well suited for CP-CML patients with existing cardiovascular comorbidities. However, it was not recommended for patients with gastrointestinal, pancreatic, or renal abnormalities. This review aims to put forth expert opinion and guidance document on key considerations for CP-CML clinical decision-making in India. |
| format | Article |
| id | doaj-art-3f8103d66b6242589d14fde4f7db328f |
| institution | Kabale University |
| issn | 0971-5851 0975-2129 |
| language | English |
| publishDate | 2024-08-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | Indian Journal of Medical and Paediatric Oncology |
| spelling | doaj-art-3f8103d66b6242589d14fde4f7db328f2025-08-20T03:44:50ZengThieme Medical and Scientific Publishers Pvt. Ltd.Indian Journal of Medical and Paediatric Oncology0971-58510975-21292024-08-01450427928510.1055/s-0042-1756477The Role of Bosutinib in Chronic Myeloid Leukemia: An Indian PerspectiveMohan Bajranglal Agarwal0Manthanathu Joseph John1https://orcid.org/0000-0003-0820-7332Punit Jain2https://orcid.org/0000-0003-3711-1014Ashok Kumar Vaid3Ajay Bapna4Maheboob Basade5Palanki Satya Dattatreya6Anupam Chakrapani7Vijay Ramanan8R. Varadarajan9Murali Subramanian10Chirag Aniruddha Shah11Narayanakutty Warrier12Subhaprakash Sanyal13Tyavanagi Shankarmurthy Ashwin14Nagendra Ramanjinappa15https://orcid.org/0000-0003-2717-3772Department of Hematology, Lilavati Hospital and Research Center, Mumbai, Maharashtra, IndiaDepartment of Hemato-Oncology, Christian Medical College, Ludhiana, Punjab, IndiaApollo Hospitals, Navi Mumbai, Maharashtra, IndiaDepartment of Oncology, Medanta, Gurgaon, Haryana, IndiaDepartment of Oncology, Bhagwan Mahaveer Cancer Hospital and Research Center, Jaipur, Rajasthan, IndiaJaslok Hospital, Mumbai, Maharashtra, IndiaOmega Hospitals, Hyderabad, Telangana, IndiaBMT Apollo Gleneagles Hospital, Kolkata, West Bengal, IndiaClinical Hematology, Bone Marrow and Stem Cell Transplant, Yashoda Hematology Clinic, Pune, Maharashtra, IndiaCenter for Blood Disorder, Chennai, Tamil Nadu, IndiaColumbia Asia Hospital, Bangalore, Karnataka, IndiaApollo CBCC Cancer Care hospital, Ahmedabad, Gujarat, IndiaMVR Cancer Center and Research Institute, Calicut, Kerala, IndiaFortis Hospital, Mumbai, Maharashtra, IndiaMylan Pharmaceuticals Private Limited (A Viatris Company), Prestige Tech Park, Kadubeesanahalli, Bengaluru, Karnataka, IndiaMylan Pharmaceuticals Private Limited (A Viatris Company), Prestige Tech Park, Kadubeesanahalli, Bengaluru, Karnataka, IndiaManagement of chronic myeloid leukemia (CML) has been transformed by the use of tyrosine kinase inhibitors (TKIs). Presently in India, five TKIs are approved for the management of CML with distinct safety profiles. The selection of TKIs for chronic phase (CP)-CML patients is based on treatment goals, underlying comorbidities, and specific TKI toxicity profiles. Bosutinib is one of five TKIs indicated for the first-line treatment of CP-CML and patients with intolerance or resistance to prior TKI therapy. It possesses a distinct safety profile among other TKIs, with less cardiovascular adverse events (AEs), albeit the liver-related and gastrointestinal AEs have higher occurrence. The safety and efficacy of bosutinib have been examined in clinical trials; however, there is a paucity of data from Asia. A virtual expert panel meeting was convened to gather expert opinion from India on the selection of bosutinib as a treatment choice for patients with CP-CML. This is a white paper document drafted with the help of an expert panel of 14 oncologists and hematooncologists from India on bosutinib use in CP-CML. The experts concurred that bosutinib has proven efficacy for CP-CML in global randomized clinical trials and is well suited for CP-CML patients with existing cardiovascular comorbidities. However, it was not recommended for patients with gastrointestinal, pancreatic, or renal abnormalities. This review aims to put forth expert opinion and guidance document on key considerations for CP-CML clinical decision-making in India.http://www.thieme-connect.de/DOI/DOI?10.1055/s-0042-1756477chronic myeloid leukemiaIndiabosutinibtyrosine kinase inhibitorschronic phase |
| spellingShingle | Mohan Bajranglal Agarwal Manthanathu Joseph John Punit Jain Ashok Kumar Vaid Ajay Bapna Maheboob Basade Palanki Satya Dattatreya Anupam Chakrapani Vijay Ramanan R. Varadarajan Murali Subramanian Chirag Aniruddha Shah Narayanakutty Warrier Subhaprakash Sanyal Tyavanagi Shankarmurthy Ashwin Nagendra Ramanjinappa The Role of Bosutinib in Chronic Myeloid Leukemia: An Indian Perspective Indian Journal of Medical and Paediatric Oncology chronic myeloid leukemia India bosutinib tyrosine kinase inhibitors chronic phase |
| title | The Role of Bosutinib in Chronic Myeloid Leukemia: An Indian Perspective |
| title_full | The Role of Bosutinib in Chronic Myeloid Leukemia: An Indian Perspective |
| title_fullStr | The Role of Bosutinib in Chronic Myeloid Leukemia: An Indian Perspective |
| title_full_unstemmed | The Role of Bosutinib in Chronic Myeloid Leukemia: An Indian Perspective |
| title_short | The Role of Bosutinib in Chronic Myeloid Leukemia: An Indian Perspective |
| title_sort | role of bosutinib in chronic myeloid leukemia an indian perspective |
| topic | chronic myeloid leukemia India bosutinib tyrosine kinase inhibitors chronic phase |
| url | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0042-1756477 |
| work_keys_str_mv | AT mohanbajranglalagarwal theroleofbosutinibinchronicmyeloidleukemiaanindianperspective AT manthanathujosephjohn theroleofbosutinibinchronicmyeloidleukemiaanindianperspective AT punitjain theroleofbosutinibinchronicmyeloidleukemiaanindianperspective AT ashokkumarvaid theroleofbosutinibinchronicmyeloidleukemiaanindianperspective AT ajaybapna theroleofbosutinibinchronicmyeloidleukemiaanindianperspective AT maheboobbasade theroleofbosutinibinchronicmyeloidleukemiaanindianperspective AT palankisatyadattatreya theroleofbosutinibinchronicmyeloidleukemiaanindianperspective AT anupamchakrapani theroleofbosutinibinchronicmyeloidleukemiaanindianperspective AT vijayramanan theroleofbosutinibinchronicmyeloidleukemiaanindianperspective AT rvaradarajan theroleofbosutinibinchronicmyeloidleukemiaanindianperspective AT muralisubramanian theroleofbosutinibinchronicmyeloidleukemiaanindianperspective AT chiraganiruddhashah theroleofbosutinibinchronicmyeloidleukemiaanindianperspective AT narayanakuttywarrier theroleofbosutinibinchronicmyeloidleukemiaanindianperspective AT subhaprakashsanyal theroleofbosutinibinchronicmyeloidleukemiaanindianperspective AT tyavanagishankarmurthyashwin theroleofbosutinibinchronicmyeloidleukemiaanindianperspective AT nagendraramanjinappa theroleofbosutinibinchronicmyeloidleukemiaanindianperspective AT mohanbajranglalagarwal roleofbosutinibinchronicmyeloidleukemiaanindianperspective AT manthanathujosephjohn roleofbosutinibinchronicmyeloidleukemiaanindianperspective AT punitjain roleofbosutinibinchronicmyeloidleukemiaanindianperspective AT ashokkumarvaid roleofbosutinibinchronicmyeloidleukemiaanindianperspective AT ajaybapna roleofbosutinibinchronicmyeloidleukemiaanindianperspective AT maheboobbasade roleofbosutinibinchronicmyeloidleukemiaanindianperspective AT palankisatyadattatreya roleofbosutinibinchronicmyeloidleukemiaanindianperspective AT anupamchakrapani roleofbosutinibinchronicmyeloidleukemiaanindianperspective AT vijayramanan roleofbosutinibinchronicmyeloidleukemiaanindianperspective AT rvaradarajan roleofbosutinibinchronicmyeloidleukemiaanindianperspective AT muralisubramanian roleofbosutinibinchronicmyeloidleukemiaanindianperspective AT chiraganiruddhashah roleofbosutinibinchronicmyeloidleukemiaanindianperspective AT narayanakuttywarrier roleofbosutinibinchronicmyeloidleukemiaanindianperspective AT subhaprakashsanyal roleofbosutinibinchronicmyeloidleukemiaanindianperspective AT tyavanagishankarmurthyashwin roleofbosutinibinchronicmyeloidleukemiaanindianperspective AT nagendraramanjinappa roleofbosutinibinchronicmyeloidleukemiaanindianperspective |